Search results for "Vaccination"
Higher risk for DVT, PE, bleeding seen after COVID-19; long-term risk for VTE recurrence may be low
A Swedish study found that patients who had COVID-19 were at higher risk for a first deep venous thrombosis (DVT) for up to three months, pulmonary embolism (PE) for up to six months, and bleeding for up to two months, while a single-center study from France found that risk for venous thromboembolism (VTE) recurrence up to a year after COVID-19 was low.
https://immattersacp.org/weekly/archives/2022/04/12/2.htm
12 Apr 2022
National Influenza Vaccination Week prompts reminder on flu shots
Online resources are available to help physicians and health care professionals ensure that patients receive the correct immunizations in accordance with the CDC's Recommended Adult Immunization Schedule.
https://immattersacp.org/weekly/archives/2015/12/08/5.htm
8 Dec 2015
CDC releases interim monkeypox guidance, reports epidemiologic and clinical characteristics
The interim guidance focused on prevention and treatment of monkeypox in persons with HIV infection. The most frequently reported signs and symptoms from recent cases of monkeypox in the U.S. include rash (100%), fever (63%), chills (59%), and lymphadenopathy (59%).
https://immattersacp.org/weekly/archives/2022/08/16/1.htm
16 Aug 2022
Pneumococcal vaccination rates suboptimal in adults with asthma
A total of 42.0% of the study sample reported ever receiving a pneumococcal vaccine, with rates below this threshold in those ages 18 to 44 years (32.7%), men (39.0%), and those with a college degree (36.7%), among other groups, researchers found.
https://immattersacp.org/weekly/archives/2017/10/03/1.htm
3 Oct 2017
ACIP revises recommendations on pneumococcal vaccine intervals for older adults
The Advisory Committee on Immunization Practices (ACIP) had previously recommended an interval of 6 to 12 months for the PCV13-PPSV23 sequence in immunocompetent adults 65 years or age and older. After review of the evidence, a new interval is now recommended.
https://immattersacp.org/weekly/archives/2015/09/15/5.htm
15 Sep 2015
Studies look at effectiveness of bivalent booster, fluvoxamine plus inhaled budesonide for COVID-19
After four weeks, bivalent booster vaccines were 47.5% effective against hospitalization or death from COVID-19, a study in North Carolina found, while a Brazilian trial showed that fluvoxamine plus inhaled budesonide significantly reduced the risk of progression to severe disease among high-risk patients with symptomatic COVID-19.
https://immattersacp.org/weekly/archives/2023/04/18/2.htm
18 Apr 2023
Recommendations on avoiding drug-drug interactions, data on recovery after ventilation
A panel of experts offered advice on avoiding drug-drug interactions when prescribing nirmatrelvir-ritonavir for patients with COVID-19, and two studies offered good news about postdischarge outcomes in COVID-19 patients who underwent a tracheostomy.
https://immattersacp.org/weekly/archives/2022/03/01/4.htm
1 Mar 2022
ACIP adds new vaccine to HPV recommendations
The Advisory Committee on Immunization Practices (ACIP) recommended the 9-valent human papillomavirus (HPV) vaccine (Gardasil 9) in last week's Morbidity and Mortality Weekly Report (MMWR).
https://immattersacp.org/weekly/archives/2015/03/31/4.htm
31 Mar 2015
Latest COVID-19 research on VTE risk, treatment with metformin, ivermectin, fluvoxamine
Unvaccinated patients may have higher risk of venous thromboembolism (VTE) when mildly ill, one study found, while another showed no effect from metformin, ivermectin, or fluvoxamine. Research supported the safety of the mRNA vaccines, and the NIH updated its treatment guidelines.
https://immattersacp.org/weekly/archives/2022/08/23/4.htm
23 Aug 2022
New COVID-19 boosters authorized and recommended
The CDC has recommended the new formulations of the mRNA vaccines, targeted at the BA.4 and BA.5 lineages of the omicron variant, for adults and adolescents who last received a COVID-19 shot at least two months ago.
https://immattersacp.org/weekly/archives/2022/09/06/2.htm
6 Sep 2022